Virobay
2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more
2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more
2010 – Virobay closes Series B financing
2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple development candidates are poised for Phase I
2007 – In-licensed cathepsin protease inhibitor assets
2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C
2006 – Founded as a protease inhibitor drug discovery and development company
Publications and Presentations
Poster Presentation, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, November 2011, San Francisco, USA
Leslie J. Holsinger, Alysia Ondoua-Lozano, Jade Rodriguez, Katherine Hanlon, Edward J. Bilsky, Joshua Havelin, Jeffrey M. Dener, Robert Booth, Todd W. Vanderah
Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer
Poster Presentation, AASLD Annual Meeting, November 2010, Boston, USA
Leslie J. Holsinger, Dion F. Coakley, Jeffrey M. Dener, Michael J. Green, Robert Booth, Stacie A. Dalrymple
Efficacy of a Reversible Cathepsin B Inhibitor in a Rodent Model of Liver Fibrosis and Human Pharmacokinetic Profile
Poster Presentation, Pain 2010: Bench to Bedside Frontiers of Clinical Investigation Symposium, October 2010, San Diego, CA. USA
Leslie J. Holsinger, John Grist, Anna K. Clark, Robert Booth, Marzia Malcangio, Stacie A. Dalrymple
Systemic Inhibition of Cathepsin S Attenuates Hypersensitivity in Animal Models of Neuropathic and Inflammatory Pain
Biochimie. 2010 May 4. [Epub ahead of print]
Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA
Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model
Poster Presentation, Society for Neuroscience, October 2009, Chicago, USA
Stacie A. Dalrymple, John Grist, Anna K. Clark, and Marzia Malcangio
Systemic Inhibition of Cathepsin S Attenuates Vincristine-Induced Neuropathic Hypersensitivity
Poster Presentation, Society of Investigative Dermatology, May 2009, Montreal, Canada
Leslie J. Holsinger, Simonetta Mocci, John O. Link, Kyle Elrod ,Michael J. Green, Robert Booth, Stacie A. Dalrymple
Characterization of VBY-129, a Cathepsin S Inhibitor Efficacious in a Mouse Model of Psoriasis
Oral Presentation: The American Pain Society Annual Meeting, May 2009, San Diego CA. USA
Stacie A. Dalrymple, Nigel Calcutt, Teresa Mixcoatl-Zecuatl, John Grist, Marzia Malcangio, John Link
A selective cathepsin S inhibitor, VBY-285, reverses allodynia in a rat model of diabetic neuropathy